NCT Number: NCT02101008
Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy
Primary Objectives Determine the response rate associated with treatment of refractory disseminated malignant melanoma with disulfiram and chelated zinc.
Secondary Objectives Determine the progression-free survival associated with treatment of refractory disseminated malignant melanoma with disulfiram and chelated zinc.
Determine the overall survival associated with treatment of refractory disseminated malignant melanoma with disulfiram and chelated zinc.
Determine the toxicity associated with treatment of refractory disseminated malignant melanoma with disulfiram and chelated zinc Determine the effect of disulfiram and chelated zinc on in vivo protein S-glutathionylation.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The subjects must fulfill all the following inclusion criteria to be eligible for participation in the study, unless otherwise specified:
- Male and female patients with stage IV melanoma cancer with biopsy proven metastases demonstrated by imaging studies. Extent of disease should be documented by CT scanning of the chest, abdomen and pelvis, or PET/CT scanning. At least one site of disease should be measurable by RECIST criteria.
- Age of 18 years or more
- ECOG performance status of 0 - 2
- Patients must have received and progressed after or not responded to at least one cycle of first line therapy (chemotherapy, biotherapy, or biochemotherapy) or are unwilling or ineligible to undergo standard therapy
- Patients with brain metastases along with disease at other sites are eligible to participate if their brain disease has been treated with surgery or radiation
- Not currently receiving other cancer chemotherapy
- Not currently participating in another study
- Baseline AST and ALT not greater than 2.0 X upper limit of normal
- Able and willing to provide informed consent and to comply with study procedures
- Able to ingest oral medications
- No known allergy to disulfiram or zinc gluconate
- Willing to refrain from ingestion of alcoholic beverages while on the study
- Serum copper within the normal range at baseline, or if outside the normal range, the PI will review for clinical significance
Exclusion criteria
Potential study subjects who meet any of the following criteria are not eligible for participation in the study:
- Participation in another clinical trial of a therapeutic drug during the past 30 days
- Addiction to alcohol or cocaine
- Baseline AST or ALT greater than 2.0 X upper limit of normal
- Unable to ingest oral medications
- Unable to undergo CT scanning because of inability to lie recumbent in the scanner;
- Actively receiving cytotoxic cancer chemotherapy agents
- Evidence of thiuram allergy (may present as contact allergy to rubber or elastic)
- Current use of sertraline and cyclosporine
- Women of child-bearing potential who are not using a commonly accepted effective means of contraception; women of child-bearing potential will have a pregnancy test before enrollment
- Need for warfarin or theophylline, the metabolism of which is likely influenced by disulfiram
- Pregnant women and nursing mothers are not allowed to enroll on this study
- Patients who are taking medications metabolized by cytochrome P450 2E1, including chlorzoxazone or halothane and its derivatives
Treatment and study plan
Primary outcomes
-
Overall Response Rate to Treatment of Melanoma With Disulfiram and Chelated Zinc
Time frame: Response to treatment will be measured by RECIST evaluation at disease assessment time-points from date of randomization until the date of first documented progression or death from any cause whichever came first (up to 15 months.)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT scanning of the chest, abdomen and pelvis, or PET/CT scanning.: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Secondary outcomes
-
Progression Free Survival
Time frame: Every 56 days - for up to two years
Sponsors and collaborators
Lead sponsor
University of Utah
Other
Registry information
Important dates
- Study start
- 2010
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Apr 1, 2014
- Registry last updated
- Dec 13, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
NCT02718066
Adenocarcinoma, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial DetailsA Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
NCT00429312
Melanoma, Neoplasms
Los Angeles, California, United States
View Trial DetailsValidation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy
NCT06666634
Genital Diseases, Genital Diseases, Male
Amsterdam, Netherlands
View Trial DetailsSelection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
NCT02724488
Head and Neck Cancer, Head and Neck Neoplasms
View Trial Details